- Home
- LIXT vs SCNX Comparison
LIXT vs SCNX Comparison
Compare LIXT & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- SCNX
- Stock Information
- Founded
- LIXT 2005
- SCNX 2010
- Country
- LIXT United States
- SCNX United States
- Employees
- LIXT N/A
- SCNX N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- SCNX Other Pharmaceuticals
- Sector
- LIXT Health Care
- SCNX Health Care
- Exchange
- LIXT Nasdaq
- SCNX Nasdaq
- Market Cap
- LIXT 24.4M
- SCNX 21.2M
- IPO Year
- LIXT N/A
- SCNX 2020
- Fundamental
- Price
- LIXT $4.81
- SCNX N/A
- Analyst Decision
- LIXT
- SCNX
- Analyst Count
- LIXT 0
- SCNX 0
- Target Price
- LIXT N/A
- SCNX N/A
- AVG Volume (30 Days)
- LIXT 155.1K
- SCNX 432.5K
- Earning Date
- LIXT 11-11-2025
- SCNX 11-05-2025
- Dividend Yield
- LIXT N/A
- SCNX N/A
- EPS Growth
- LIXT N/A
- SCNX N/A
- EPS
- LIXT N/A
- SCNX N/A
- Revenue
- LIXT N/A
- SCNX $128,202.00
- Revenue This Year
- LIXT N/A
- SCNX N/A
- Revenue Next Year
- LIXT N/A
- SCNX N/A
- P/E Ratio
- LIXT N/A
- SCNX N/A
- Revenue Growth
- LIXT N/A
- SCNX N/A
- 52 Week Low
- LIXT $0.64
- SCNX $0.69
- 52 Week High
- LIXT $6.26
- SCNX $9.55
- Technical
- Relative Strength Index (RSI)
- LIXT 51.75
- SCNX 31.37
- Support Level
- LIXT $4.77
- SCNX $0.75
- Resistance Level
- LIXT $5.53
- SCNX $0.89
- Average True Range (ATR)
- LIXT 0.47
- SCNX 0.05
- MACD
- LIXT -0.08
- SCNX 0.02
- Stochastic Oscillator
- LIXT 21.66
- SCNX 16.53
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.